deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03979508

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)

Sponsor: Mayo Clinic

Conditions Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Breast Ductal Carcinoma In Situ Breast Fibrocystic Change Breast Lobular Carcinoma In Situ Invasive Breast Carcinoma Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma
Interventions Abemaciclib Therapeutic Conventional Surgery
Updated 20 times since 2019 Last updated: Nov 7, 2025 Started: Jan 10, 2020 Primary completion: Dec 26, 2024 Completion: Dec 26, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.

Other terminated trials from Mayo Clinic

See all terminations from Mayo Clinic

Other Anatomic Stage I Breast Cancer AJCC v8 trials with similar outcome

Browse all Anatomic Stage I Breast Cancer AJCC v8 trials

Listed as NCT03979508, this PHASE2 trial focuses on Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 and remains terminated or withdrawn. Sponsored by Mayo Clinic, it has been updated 20 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~May 2024 · 9 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

20 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 15 earlier versions

  1. Aug 2023 — May 2024 [monthly]

    Recruiting PHASE2

  2. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  3. Mar 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  4. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  5. Jul 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  6. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  10. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  11. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  13. Dec 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE2

  14. Sep 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

  15. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations